MedPath

Acne cure rate in patients Hyperandrogenism with two drugs of Decuttane and CYPROTERONE COMPOUND .

Not Applicable
Conditions
Acne vulgaris.
acne vulgaris
Registration Number
IRCT2013110315246N1
Lead Sponsor
Isfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
30
Inclusion Criteria

age between 14-45 years old; besides acne hirsutism (Ferriman & Gallwey score greater than or equal to 4) and Ludwing grade one or higher female androgenetic alopecia; absence of contraindications to treatment with tablets decuttane and CYPROTERONE COMPOUND based on questionnaire; not wanting to at least 9 months of pregnancy, or breast-feeding; individual patients signed a consent form
Exclusion criteria: drug allergy; pregnancy or lactation; uncooperative patient or patient's consent to continue reading.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of acne vulgaris lesions. Timepoint: Baseline, three months and one month after the end of treatment. Method of measurement: Indices are calculated based on the Total Acne lesion Count( TLC) and acne severity index (ASI) for each patient.
Secondary Outcome Measures
NameTimeMethod
Side effects of drug. Timepoint: Every 6 weeks. Method of measurement: clinical evaluation-liver function test and lipid profile.
© Copyright 2025. All Rights Reserved by MedPath